1.70
price down icon0.40%   -0.01
 
loading
Schlusskurs vom Vortag:
$1.71
Offen:
$1.68
24-Stunden-Volumen:
12,378
Relative Volume:
0.50
Marktkapitalisierung:
$66.99M
Einnahmen:
$1.55M
Nettoeinkommen (Verlust:
$-27.51M
KGV:
-2.00
EPS:
-0.85
Netto-Cashflow:
$-50.09M
1W Leistung:
-1.33%
1M Leistung:
-26.91%
6M Leistung:
-36.21%
1J Leistung:
+87.15%
1-Tages-Spanne:
Value
$1.66
$1.7031
1-Wochen-Bereich:
Value
$1.5016
$1.96
52-Wochen-Spanne:
Value
$0.7777
$4.00

Beyondspring Inc Stock (BYSI) Company Profile

Name
Firmenname
Beyondspring Inc
Name
Telefon
-
Name
Adresse
-
Name
Mitarbeiter
36
Name
Nächster Verdiensttermin
2024-08-05
Name
Neueste SEC-Einreichungen
Name
BYSI's Discussions on Twitter

Vergleichen Sie BYSI mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
BYSI 1.7031 66.99M 1.55M -27.51M -50.09M -0.85
VRTX 449.99 115.43B 10.63B -479.80M -1.35B 13.33
REGN 747.25 82.04B 13.85B 4.65B 3.32B 35.06
ARGX 593.04 35.30B 1.86B -40.29M -1.28B -4.16
ALNY 245.84 32.04B 2.09B -332.26M 16.06M -4.14
BNTX 107.23 24.89B 3.30B -501.07M 1.03B 11.54

Beyondspring Inc Stock (BYSI) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2021-12-02 Herabstufung BofA Securities Buy → Underperform
2021-12-02 Herabstufung Jefferies Buy → Hold
2021-12-01 Herabstufung H.C. Wainwright Buy → Neutral
2021-12-01 Herabstufung William Blair Outperform → Mkt Perform
2021-09-09 Eingeleitet Robert W. Baird Outperform
2021-08-04 Hochstufung H.C. Wainwright Neutral → Buy
2021-04-05 Herabstufung H.C. Wainwright Buy → Neutral
2021-01-11 Eingeleitet BofA Securities Buy
2020-12-29 Eingeleitet Evercore ISI Outperform
2020-02-07 Eingeleitet Jefferies Buy
2020-01-10 Eingeleitet Nomura Buy
2019-12-03 Eingeleitet William Blair Outperform
2019-07-10 Bestätigt H.C. Wainwright Buy
2019-04-30 Herabstufung Maxim Group Buy → Hold
2018-10-25 Bestätigt Maxim Group Buy
Alle ansehen

Beyondspring Inc Aktie (BYSI) Neueste Nachrichten

pulisher
07:12 AM

Non-small Cell Lung Cancer Treatment Market 2032: Clinical Trials, Medication, Prevalence, Incidence, Therapies, EMA, PDMA, FDA Approvals, and Companies by DelveInsight - The Globe and Mail

07:12 AM
pulisher
Nov 20, 2024

Amazon.com Inc (AMZN-Q) QuotePress Release - The Globe and Mail

Nov 20, 2024
pulisher
Nov 11, 2024

NK Cell Therapy Clinical Trial Pipeline Appears Robust With 140+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Malaysian Reserve

Nov 11, 2024
pulisher
Nov 11, 2024

BeyondSpring Presents Updated Efficacy Results from a Phase - GlobeNewswire

Nov 11, 2024
pulisher
Nov 11, 2024

BeyondSpring's Lung Cancer Drug Shows 89% Disease Control Rate in Phase 2 Trial | BYSI Stock News - StockTitan

Nov 11, 2024
pulisher
Nov 05, 2024

ROS1 Inhibitors Market Booms as Demand for Targeted Cancer Therapies Escalates | DelveInsight - The Malaysian Reserve

Nov 05, 2024
pulisher
Nov 04, 2024

BeyondSpring (BYSI) Stock Drops Amid Biotech Sector Volatility - GuruFocus.com

Nov 04, 2024
pulisher
Nov 04, 2024

Neutropenia Treatment Market to hit USD 20.8 billion by 2032, says Global Market Insights Inc. - GlobeNewswire

Nov 04, 2024
pulisher
Oct 31, 2024

BioWorld Cancer Index continues to decline amid broader market gains - BioWorld Online

Oct 31, 2024
pulisher
Oct 26, 2024

Biotech Stocks Facing FDA Decision In November - RTTNews

Oct 26, 2024
pulisher
Oct 16, 2024

BYSI (BeyondSpring) Cash From Discontinued Investing Activi - GuruFocus.com

Oct 16, 2024
pulisher
Oct 15, 2024

Marshall Wace LLP Buys Shares of 10,538 Poseida Therapeutics, Inc. (NASDAQ:PSTX) - Defense World

Oct 15, 2024
pulisher
Oct 15, 2024

Renaissance Technologies LLC Increases Stock Holdings in Mesa Air Group, Inc. (NASDAQ:MESA) - Defense World

Oct 15, 2024
pulisher
Oct 14, 2024

CDK4/6 Inhibitors Market to Grow at Healthy Growth Rate by 2034 Owing to Expanded Usage of Approved Blockbuster CDK4/6 Inhibitors in Early-stage Breast Cancer and the Emergence of Newer Players in Other Indications | DelveInsight - PR Newswire UK

Oct 14, 2024
pulisher
Oct 14, 2024

Caspase 8 Market Analysis, Trends, Growth, Research And Forecast 2030 - La Funcion mx

Oct 14, 2024
pulisher
Oct 02, 2024

G-CSF (Granulocyte Colony Stimulating Factors) Market Size, Analysis, Trends, Overview And Forecast To 2033 - WhaTech

Oct 02, 2024
pulisher
Oct 02, 2024

BYSI Sees Quick 5.39% Surge Amid Low Trading Volume - GuruFocus.com

Oct 02, 2024
pulisher
Sep 30, 2024

BYSI: BeyondSpring Inc. Stock Surges 7.27% Amid Market Fluctuati - GuruFocus.com

Sep 30, 2024
pulisher
Sep 27, 2024

BeyondSpring (BYSI) Stock Surges 6.83% Amid High Volume Trading - GuruFocus.com

Sep 27, 2024
pulisher
Sep 22, 2024

Acadian Asset Management LLC Has $34,000 Stock Position in BeyondSpring Inc. (NASDAQ:BYSI) - Defense World

Sep 22, 2024
pulisher
Sep 17, 2024

Chemotherapy Induced Neutropenia Market Size is Set for Rapid - openPR

Sep 17, 2024
pulisher
Sep 17, 2024

BeyondSpring reports promising phase 2 NSCLC study results - Investing.com

Sep 17, 2024
pulisher
Sep 16, 2024

BeyondSpring plinabulin, Merck Keytruda combo shows promise in NSCLC - MSN

Sep 16, 2024
pulisher
Sep 16, 2024

BeyondSpring reports safer NSCLC therapy option - Investing.com India

Sep 16, 2024
pulisher
Sep 16, 2024

BeyondSpring Presents Final Data Analysis of DUBLIN-3 Phase 3 Study in 2L/3L EGFR Wild-type NSCLC at ESMO Congress 2024 - StockTitan

Sep 16, 2024
pulisher
Sep 16, 2024

BeyondSpring Presents Efficacy/Safety Results from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at ESMO Congress 2024 - StockTitan

Sep 16, 2024
pulisher
Sep 16, 2024

BeyondSpring presented interim Phase 2 data on 303 Study - TipRanks

Sep 16, 2024
pulisher
Sep 16, 2024

BeyondSpring Presents Efficacy/Safety Results from a Phase - GlobeNewswire

Sep 16, 2024
pulisher
Sep 16, 2024

BeyondSpring Presents Final Data Analysis of DUBLIN-3 Phase - GlobeNewswire

Sep 16, 2024
pulisher
Sep 12, 2024

BeyondSpring (NASDAQ:BYSI) Trading Up 3.3% - MarketBeat

Sep 12, 2024
pulisher
Sep 10, 2024

BeyondSpring Delivers Oral Presentation at ISLAC 2024 World Conference on Lung Cancer of its Lead Anti-Cancer Asset Plinabulin Showcasing Positive Final Phase 3 Data in 2L/3L NSCLC EGFR Wild-Type... - Markets Insider

Sep 10, 2024
pulisher
Sep 10, 2024

BeyondSpring announces Dublin-3 final phase 3 efficacy data - TipRanks

Sep 10, 2024
pulisher
Sep 10, 2024

BeyondSpring Delivers Oral Presentation at ISLAC 2024 World Conference on Lung Cancer of its Lead Anti-Cancer Asset Plinabulin Showcasing Positive Final Phase 3 Data in 2L/3L NSCLC EGFR Wild-Type with Concurrent Publication in the Lancet Respira - GlobeNewswire

Sep 10, 2024
pulisher
Sep 03, 2024

BeyondSpring Announces Oral Presentation at the 2024 World - GlobeNewswire

Sep 03, 2024
pulisher
Sep 03, 2024

BeyondSpring Announces Oral Presentation at the 2024 World Conference on Lung Cancer and Two Poster Presentations During ESMO Congress 2024 Showcasing its Lead Anti-Cancer Asset, Plinabulin - StockTitan

Sep 03, 2024
pulisher
Aug 31, 2024

Is BeyondSpring (NASDAQ:BYSI) In A Good Position To Invest In Growth? - Yahoo Finance

Aug 31, 2024
pulisher
Aug 29, 2024

BeyondSpring Inc. Reports Mid-Year Financials - TipRanks

Aug 29, 2024
pulisher
Aug 22, 2024

Global Chemotherapy Drugs Market to Grow Substantially at a CAGR of ~9% by 2030 | DelveInsight - The Malaysian Reserve

Aug 22, 2024
pulisher
Aug 21, 2024

BeyondSpring (NASDAQ:BYSI) Stock Price Down 0.5% - MarketBeat

Aug 21, 2024
pulisher
Aug 19, 2024

BYSI (BeyondSpring) EV-to-Revenue : 40.75 (As of Aug. 19, 2024) - GuruFocus.com

Aug 19, 2024
pulisher
Aug 18, 2024

BYSI (BeyondSpring) GF Value Rank : 10 (As of Aug. 18, 2024) - GuruFocus.com

Aug 18, 2024
pulisher
Aug 18, 2024

BYSI (BeyondSpring) 3-Year Dividend Growth Rate : 0.00% (As of Dec. 2023) - GuruFocus.com

Aug 18, 2024
pulisher
Aug 13, 2024

Asia Deal Watch: Ocumension Obtains Chinese Rights To Eight Alcon Products - Scrip

Aug 13, 2024
pulisher
Aug 12, 2024

BioWorld Cancer Index drops overall; Blueprint, TG catapulted in Q1 - BioWorld Online

Aug 12, 2024
pulisher
Aug 07, 2024

Chemotherapy Induced Neutropenia Market Forecasted to Surge - openPR

Aug 07, 2024
pulisher
Aug 06, 2024

SEED Therapeutics (SEED) Enters into Strategic Research - GlobeNewswire

Aug 06, 2024
pulisher
Aug 06, 2024

SEED Therapeutics (SEED) Enters into Strategic Research Collaboration with Eisai Co., Ltd. to Discover and Develop Novel Molecular Glue Degraders for Neurodegeneration and Oncology Indications - StockTitan

Aug 06, 2024
pulisher
Aug 01, 2024

Global Cancer Supportive Care Drugs Market to Cross 17 Billion Mark by 2030| DelveInsight - 新浪香港

Aug 01, 2024
pulisher
Aug 01, 2024

Drugs for Traveler’s Diarrhea Industry to Witness an Outstanding Growth by 2030 |GSK, Salix Pharmaceuticals, Chiesi Farm – Moose Gazette - Moose Gazette

Aug 01, 2024
pulisher
Jul 31, 2024

O Shaughnessy Asset Management LLC Buys 21,202 Shares of Haleon plc (NYSE:HLN) - Defense World

Jul 31, 2024
pulisher
Jul 31, 2024

Cencora (NYSE:COR) Releases FY 2024 Earnings Guidance - Defense World

Jul 31, 2024

Finanzdaten der Beyondspring Inc-Aktie (BYSI)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$18.98
price up icon 1.80%
$70.68
price down icon 0.42%
$38.38
price up icon 3.49%
$369.83
price up icon 1.48%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Kapitalisierung:     |  Volumen (24h):